# Acrigen Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acrigen-biosciences

- Industry: Biotechnology
- Headquarters: Alameda, US
- Website: www.acrigen.com
- Latest round: Seed (Sep 28, 2021)
- Investors on record: 4

## About

Based in CA, US, and founded in 2019, Acrigen Biosciences, Inc. provides a pipeline of therapies to treat genetic disorders. In March 2022, the firm received USD 1 million from investor The National Science Foundation.

The company develops Precision Gene Editing Systems which harness the power of CRISPR which is used in human therapeutics. Utilizing ErAcrs (engineered anti-CRISPR proteins) and revolutionary aCas and µCas CRISPR gene editors, Acrigen's unique technology develops an editing toolkit.

## Funding rounds

- Seed, Sep 28, 2021 — Alexandria Venture Investments, Dolby Family Ventures, Berkeley Catalyst Fund, Red Tree Venture Capital

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Seed
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Seed
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Seed